Trump Halt To US Funding For WHO: Making Global Health, Government Organization Potent Issues
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
You may also be interested in...
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.